Form 4: Edwards Lifesciences Director Michael Mussallem Executes Stock Option and Sells Shares

Director Michael Mussallem exercised stock options and sold shares of Edwards Lifesciences (EW) on April 4, 2024, according to a Form 4 filing with the SEC.

Summary

• Michael Mussallem, a director at Edwards Lifesciences, executed an employee stock option on April 4, 2024, acquiring 29,350 shares at a price of $36.75.
• On the same day, Mussallem sold shares of Edwards Lifesciences in multiple transactions at varying prices.
• He sold 200 shares at a weighted average price of $94.19, 2,712 shares at $93.72, 9,820 shares at $91.54, and 16,618 shares at $92.70.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 15, 2023.
• Following these transactions, Mussallem directly owns 4,485.82 shares and indirectly owns 4,038,377 shares through a living trust.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports transactions executed under a pre-existing trading plan. There's no indication of positive or negative implications for the company.

Industry Context

Form 4 filings are standard disclosures required by the SEC when corporate insiders, like directors and officers, trade their company's stock. These filings provide transparency into insider transactions and are closely watched by investors.

Comparison to Industry Standards

• Comparing Mussallem's transactions to those of other directors in similar medical device companies would require analyzing their Form 4 filings.
• Generally, the use of 10b5-1 plans is a common practice among corporate insiders to avoid accusations of insider trading, aligning with industry standards for compliance and ethical trading.

Stakeholder Impact

• The transactions may have a minor impact on shareholders as they reflect insider trading activity, but the use of a 10b5-1 plan mitigates concerns about opportunistic trading.

Key Dates